Takeda Pharmaceutical Officer Files Form 144 to Sell $1.12M in ADSs

Executive Summary

On October 30, 2026, Giles Richard Platford, President of the International Business Unit at Takeda Pharmaceutical Co Ltd, submitted a Form 144 filing declaring the intention to sell 55,617 American Depositary Shares (ADSs) with an estimated market value of $1,121,794.89 through Interactive Brokers LLC, commencing on or about November 1, 2026.

Transaction & Security Details

• Securities to be Sold: 55,617 ADSs
• Aggregate Market Value: $1,121,794.89 (~$20.17 per ADS)
• Shares Outstanding: 198,318,946 ADSs
• Origin of Shares: Acquired via vested Restricted Stock Unit (RSU) awards on July 30, 2024, as compensatory equity.
• Recent Prior Activity: Mr. Platford previously sold 31,083 ADSs on August 10, 2026, generating $531,519.30 in gross proceeds to cover tax obligations relating to share vesting.

Market Impact & Trading Significance

The proposed sale represents a nominal fraction of Takeda's outstanding ADSs (<0.03%), resulting in negligible direct market impact or dilution. As the shares stem from RSU compensation and follow previous tax-related vesting transactions, this disposition appears consistent with routine executive equity diversification rather than an operational or directional signal.